Karin Walker, Chief Accounting Officer of Prothena Corp PLC (PRTA, Financial), sold 5,000 shares of the company on December 20, 2023, according to a recent SEC Filing. This transaction is part of a series of sales by the insider over the past year, totaling 70,000 shares sold, with no shares purchased in the same period.
Prothena Corp PLC is a biotechnology company focused on the discovery and development of novel therapies for patients with diseases involving protein misfolding or cell adhesion. The company is committed to bringing new treatments to market for diseases that currently have limited or no therapeutic options.
The insider transaction history for Prothena Corp PLC indicates a trend of insider sales, with 49 insider sells and no insider buys over the past year.
On the day of the insider's recent sale, shares of Prothena Corp PLC were trading at $37.19, giving the company a market cap of $1.980 billion.
The stock's price-to-GF-Value ratio stands at 0.45, with a GuruFocus Value of $83.30, suggesting that Prothena Corp PLC is a Possible Value Trap, Think Twice, according to its GF Value.
The GF Value is determined by considering historical trading multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, along with a GuruFocus adjustment factor based on the company's historical returns and growth, and future business performance estimates from Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
